Cipla Reports March 2025 Results: Strong PAT Growth Amid PBT Decline Concerns

Cipla, a prominent player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending March 2025. The evaluation changes reflect a notable shift, with the stock's score adjusting to 2 from 13 over the past three months.
The financial data reveals that Cipla's Profit After Tax (PAT) for the latest six months stands at Rs 2,792.35 crore, showcasing a year-on-year growth of 30.72%. This positive trend in PAT indicates a strong performance in the near term.

Conversely, the company has faced challenges, particularly in its Profit Before Tax (PBT), which has recorded a quarterly figure of Rs 1,214.84 crore. This represents a decline of 15.5% compared to the average PBT of Rs 1,438.51 crore over the previous four quarters, suggesting a very negative near-term trend in this area. Additionally, Cipla's non-operating income reached its highest level in the last five quarters at Rs 289.46 crore, raising questions about the sustainability of this income from non-business activities.

For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.